Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS)

Category Primary study
JournalDiabetes
Year 2021
This article has no abstract
Epistemonikos ID: 9b357117ac4fcf88d5c7c10755e2fd04e56630df
First added on: Feb 13, 2025